Company intelligence / Profile preview

ArmaGen

San Diego, California, United Statesarmagen.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

ArmaGen has developed a proprietary technology that enables therapies to cross the blood-brain barrier. Their lead candidate SHP-631 (formerly AGT-182) for Hunter syndrome reached Phase 2 clinical trials. The company achieved a clinical milestone in 2015 with dosing patients in its Phase 1 trial of AGT-182.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Fusion proteinEnzyme replacement therapy
Industry: Biotech

Partnerships

Shire plc

Beyond the preview

Go deeper on ArmaGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArmaGen.